BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

...vector carrying the GDNF gene, in Phase I testing for Parkinson's disease (PD). uniQure and Treeway B.V....
BioCentury | Jun 27, 2016
Clinical News

Edaravone regulatory update

...South Korea as Radicut for ALS. Radicut is also approved in Japan to treat stroke. Treeway B.V....
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...Tarix Orphan LLC TXA127 Formulation of the angiotensin (1-7) peptide Preclinical Company Product Description Status Treeway B.V....
BioCentury | Feb 8, 2016
Clinical News

TW001: Phase I data

...markets an IV formulation of edaravone as Radicut in Japan to treat stroke and ALS. Treeway B.V....
BioCentury | Jan 25, 2016
Emerging Company Profile

Mining ALS possibilities

...sequencing initiative into new treatments that can delay progression for much longer periods of time. Treeway...
...potentially extend the life of ALS patients was being evaluated," said CEO Inez de Greef. Treeway's...
...and EU Orphan Drug designations. Treeway plans to start a Phase II/III trial in 2Q16. Treeway...
Items per page:
1 - 5 of 5
BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

...vector carrying the GDNF gene, in Phase I testing for Parkinson's disease (PD). uniQure and Treeway B.V....
BioCentury | Jun 27, 2016
Clinical News

Edaravone regulatory update

...South Korea as Radicut for ALS. Radicut is also approved in Japan to treat stroke. Treeway B.V....
BioCentury | Feb 18, 2016
Product R&D

Crossing paths

...Tarix Orphan LLC TXA127 Formulation of the angiotensin (1-7) peptide Preclinical Company Product Description Status Treeway B.V....
BioCentury | Feb 8, 2016
Clinical News

TW001: Phase I data

...markets an IV formulation of edaravone as Radicut in Japan to treat stroke and ALS. Treeway B.V....
BioCentury | Jan 25, 2016
Emerging Company Profile

Mining ALS possibilities

...sequencing initiative into new treatments that can delay progression for much longer periods of time. Treeway...
...potentially extend the life of ALS patients was being evaluated," said CEO Inez de Greef. Treeway's...
...and EU Orphan Drug designations. Treeway plans to start a Phase II/III trial in 2Q16. Treeway...
Items per page:
1 - 5 of 5